Here, we investigated the effect of ESR, CDK4/6, and mdm2 targeting in the presence and absence of HER4 expression in three well characterized ESR-positive BC cells (i.e., MCF-7, T-47D, ZR-75-1). This evidence concerns the gene CDK4 and breast cancer.